Drug Topics April 26, 2024
Fidanacogene elaparvovec-dzkt (Beqvez) is a 1 time treatment that allows patients with hemophilia B to produce factor IX themselves.
The FDA has approved fidanacogene elaparvovec-dzkt (Beqvez) for the treatment of moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid, Pfizer announced in a release.1
Fidanacogene elaparvovec-dzkt is an adeno-associated virus-based gene therapy that imparts a functional copy of the FIX gene into transduced cells. Compared to the current standard of care, which requires intravenous infusions of FIX to be administered multiple times a week or month,...
Today's Sponsors
Today's Sponsor
